Betaine anhydrous in homocystinuria: results from the RoCH registry

Vassili ValayannopoulosEmail author View ORCID ID profile,
Manuel Schiff,
Nathalie Guffon,
Yann Nadjar,
Angels García-Cazorla,
Mercedes Martinez-Pardo Casanova,
Aline Cano,
Maria L. Couce,
Jaime Dalmau,
Luis Peña-Quintana,
Vincent Rigalleau,
Guy Touati,
Luis Aldamiz-Echevarria,
Pascal Cathebras,
Didier Eyer,
Dominique Brunet,
Léna Damaj,
Dries Dobbelaere,
Claire Gay,
Sylvie Hiéronimus,
Virginie Levrat and
François Maillot

Orphanet Journal of Rare Diseases201914:66

https://doi.org/10.1186/s13023-019-1036-2

Received: 7 November 2018
Accepted: 20 February 2019
Published: 14 March 2019

Abstract

Background

The Registry of Adult and Paediatric Patients Treated with Cystadane® – Homocystinuria (RoCH) is a non-interventional, observational, multi-centre, post-authorization safety study that aimed to identify safety of betaine anhydrous (Cystadane®) in the treatment of patients with inborn errors of homocysteine metabolism (homocystinuria) in order to minimise the treatment associated risks and establish better knowledge on its clinical use. The registry included patients of all ages with homocystinuria who were treated with betaine anhydrous in conjunction with other therapies. Clinical data were collected retrospectively from 2007 to 2013, then prospectively up to February 2014. All adverse events (AEs) reported during the study were recorded. The clinical and biological status of patients was monitored at least once a year.

Results

A total of 125 patients with homocystinuria (adults [> 18 years]: 50; paediatric [≤18 years]: 75) were enrolled at 29 centres in France and Spain. Patients were treated with betaine anhydrous for a mean duration of 7.4 ± 4.3 years. The median total daily dose of betaine anhydrous at the first and last study visits was 6 g/day for cystathionine β-synthase (CBS)-deficient vitamin B6 responders and 9 g/day for methylenetetrahydrofolate reductase-deficient patients, while the median daily dose increased in CBS-deficient B6 non-responders (from 6 to 9 g/day) and cobalamin metabolism-defective patients (from 3 to 6 g/day) between the first and last visits. Treatment caused a mean overall reduction of 29% in plasma homocysteine levels in the study population. A total of 277 AEs were reported during the study, of which two non-serious AEs (bad taste and headache) and one serious AE (interstitial lung disease) were considered to be drug related. Overall, betaine anhydrous was well tolerated with no major safety concerns.

Conclusions

Data from the RoCH registry provided real-world evidence on the clinical safety and efficacy of betaine anhydrous in the management of homocystinuria in paediatric and adult patients.